AstraZeneca

Biotechnology / Pharmaceuticals
AZN.L
GBX 10,286 3.2
Share price
$ 195 bn
Market Cap
$ 236 bn
Enterprise Value

Carbon footprint

1.1 Ton
GHG emissions per $ 1 mln investment
0.04x the weighted average for S&P 500
FY2021
How is this calculated?
-1.9%
YOY change in GHG emissions
Weaker than the -11% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-19%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -5.1% weighted average for S&P 500
FY2022
How is this calculated?

AstraZeneca aims to reduce Scope 1 + 2 by 98% by 2026 from a base year 2015


1.5°C
AstraZeneca's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

AstraZeneca's GHG emissions (market-based) (Kt of CO2e)
AstraZeneca's Carbon intensity (Tons per 1 USDm)

AstraZeneca's carbon footprint

AstraZeneca reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 267 Kt (-5.3 /-1.9% y-o-y). Also positively, carbon intensity was down at 7.1 t (-3.1 /-30.4% y-o-y).

AstraZeneca's Scope 3 emissions was up at 6,582 Kt (+596/+10% y-o-y). This is a higher growth rate than over the period since 4Q'19 (+4.8% CAGR).

The company is committed to reducing Scope 1 + 2 by 98% by 2026 from a base year 2015, which translates into the estimated reduction of -51 Kt per annum over the period of FY2022 - FY2026. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Company environmental metrics

Show more...